Fig. 1

sRAGE in healthy controls (GOLD 0) and COPD patients (GOLD 1–4). A The levels of sRAGE were assessed in plasma using the simplified immunoprecipitation in 96-well ELISA (IPE) methodology coupled to targeted liquid chromatography-mass spectrometry (LC–MS). Plasma sRAGE levels were assessed in 185 healthy individuals without airway obstruction (GOLD 0), 79 GOLD stage I COPD patients, 144 GOLD stage II COPD patients, 78 GOLD stage III COPD patients and 23 GOLD stage IV COPD patients. b The plasma levels of sRAGE in subjects homozygous for the major allele of rs2070600 (GG), heterozygous (GA), or homozygous for the minor allele of rs2070600 (AA). Data is shown as individuals data points and mean ± SEM. Statistical differences were tested using a Mann–Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001. The exact p-values are indicated where appropriate